Organisational complexity and scale are two sides of the same coin. In a quest for scale, Big Pharma companies have built large, diverse portfolios that span multiple therapeutic areas and technologies. But this comes with its own set of challenges.
Portfolio diversity leads to inevitable organisational complexity, requiring leaders to think more proactively about decision-making effectiveness, capability-building, and role clarity.
In this white paper, we explore how organisational complexity is driven by scale and portfolio diversity, and illustrate the need for operational excellence when pursuing sustainable growth, with a focus on:
- How portfolio diversity drives financial performance and organisational complexity
- How pharmaceutical companies can both grow and manage complexity
- The key learnings for pharma leaders to embed operational excellence
If Big Pharma companies want to drive long-term revenue and market capitalisation growth, they will need to evolve their operating models and embed a mindset of focus.
Download your free copy of this white paper via the button above.